<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24844">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783339</url>
  </required_header>
  <id_info>
    <org_study_id>T4032</org_study_id>
    <nct_id>NCT02783339</nct_id>
  </id_info>
  <brief_title>Neuroform Atlas Stent for Intracranial Aneurysm Treatment</brief_title>
  <acronym>ATLAS EU PMCF</acronym>
  <official_title>Evaluation of Safety and Performance of the Neuroform AtlasTM Stent System for Intracranial Aneurysm Treatment - Post Market Clinical Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate effectiveness and safety of the
      NeuroForm Atlas stent system for use in patients requiring stent assisted intracranial
      aneurysm treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multicenter, open-label, single arm post market follow-up
      registry designed to demonstrate the potential treatment of intracranial, saccular aneurysms
      with the Next Generation Neuroform Stent System. The study will evaluate the permanent
      morbidity and mortality rate within the 12 to 16 months following the procedure. The study
      will evaluate as well the percent occlusion of the treated target lesion on angiography in
      the absence of retreatment, or parent artery stenosis at the target location at 12 to 16
      months. Subjects with documented saccular aneurysms arising from a parent artery may
      potentially benefit from stent assisted coiling, provided they meet the other eligibility
      criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>16 Months</target_duration>
  <primary_outcome>
    <measure>permanent morbidity rate defined as any major ipsilateral stroke or neurolgocial death within 12 to 16 months following the procedure</measure>
    <time_frame>16 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality rate within 12 to 16 months following the procedure</measure>
    <time_frame>16 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete aneurysm occlusion of the treated target lesion on 16 month imaging</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or worsening major ipsilateral stroke as measured by NIHSS and mRS</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subarachnoid hemorrhage</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm Rupture</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Registration of patients who are willing to participate in this ATLAS PMCF registry and
        assuming they meet all of the inclusion/exclusion criteria and provided written informed
        consent should be recorded prior to implantation of the Neuroform Atlas Stent to ensure
        data capture on all enrolled and treated patients in this post-market evaluation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has an intracranial aneurysm for which an endovascular treatment requiring
             stent assisted intracranial aneurysm coiling has been decided by the site
             investigator

          2. Patient or legal representative is willing and able to provide written informed
             consent

          3. Patient is willing able to comply with scheduled visits and examinations per protocol
             requirements

        Exclusion Criteria:

          1. Patient that is younger than 18 years old at the time of entry into the study

          2. Patient with mRS &gt; 3

          3. Patient has a saccular ruptured aneurysm &lt; 3 months

          4. Patient has a fusiform aneurysm

          5. Treatment of several aneurysms during the same procedure, except adjacent aneurysms
             treated with the same stent

          6. Planned treatment of other aneurysm in the same vascular territory within the study
             time period

          7. Patient with severe vasospasm that does not respond to pharmacological therapy

          8. Aneurysm associated with an arteriovenous malformation, or any other lesion that
             could lead to hemorrhagic complications

          9. Pregnant woman or child feeding

         10. Any condition which will not allow the patient to comply with the necessary follow-up
             for this study (medical condition, patient leaving abroad)

         11. Patient with confirmed allergy to nickel titanium (Nitinol)

         12. Patient in whom antiplatelet and/or anticoagulation therapy is contraindicate

         13. Patient for whom angiography and other examinations show that access to the target
             cerebral aneurysm by the stent may be impossible because of anatomical features

         14. Patient for whom angiography and MRA/MRI is contraindicated

         15. Patient with target aneurysm previously treated with a stent -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Houdart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Lariboisière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Le Page</last_name>
    <phone>+33 1 47 10 10 37</phone>
    <email>caroline.lepage@stryker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vicki Hacker</last_name>
    <phone>510-413-2713</phone>
    <email>Vicki.hacker@stryker.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>F-33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xavier Barreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>F-34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marinette Moynier</last_name>
      <email>m-moynier@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Bonafé, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>F-75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emmanuel Houdart, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>F-75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexa Lopez</last_name>
      <email>llopes@for.paris</email>
    </contact>
    <investigator>
      <last_name>Michel Piotin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isle Kreuzer</last_name>
      <email>Ilse.Kreuzer@klinikum-augsburg.de</email>
    </contact>
    <investigator>
      <last_name>Ansgar D Berlis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadja Rieckehr</last_name>
      <email>nadja.rieckehr@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Marius Hartmann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian sebastian.fischer@kk-bochum.de, MD</last_name>
    </contact>
    <investigator>
      <last_name>Werner Weber, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität zu Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>DE-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramona Schramm</last_name>
      <email>Ramona.Schramm@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Peter Schramm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>SL-036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamil Zelenak</last_name>
    </contact>
    <investigator>
      <last_name>Kamil Zelenak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>May 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Next Generation Neuroform Stent System</keyword>
  <keyword>Intracranial</keyword>
  <keyword>Stent system</keyword>
  <keyword>Saccular aneurysm</keyword>
  <keyword>Stent assisted coiling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
